Genmab A (GMAB) Income from Continuing Operations: 2018-2021
- Genmab A's Income from Continuing Operations rose 362.62% to $169.09 in Q2 2021 from the same period last year, while for Jun 2021 it was $356.29, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $552.7 million for FY2020, which is 145.38% up from last year.
- Genmab A's Income from Continuing Operations amounted to $169.09 in Q2 2021, which was up 116.92% from $77.95 recorded in Q4 2020.
- Genmab A's 5-year Income from Continuing Operations high stood at $25.5 million for Q4 2018, and its period low was -$11.7 million during Q2 2019.
- Its 3-year average for Income from Continuing Operations is -$2.3 million, with a median of $72.69 in 2019.
- In the last 5 years, Genmab A's Income from Continuing Operations slumped by 100.00% in 2019 and then surged by 362.62% in 2021.
- Over the past 4 years, Genmab A's Income from Continuing Operations (Quarterly) stood at $25.5 million in 2018, then plummeted by 100.00% to $72.69 in 2019, then increased by 7.23% to $77.95 in 2020, then spiked by 362.62% to $169.09 in 2021.
- Its last three reported values are $169.09 in Q2 2021, $77.95 for Q4 2020, and $36.55 during Q2 2020.
